Tyra Biosciences to Present at Upcoming Investor Conferences

TYRA 11.13.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-19
Name of Upcoming Event:Jefferies London Healthcare Conference
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:36th Annual Piper Healthcare Conference
Full Press ReleaseSEC FilingsOur TYRA Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
  • 01.10.2025 - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
  • 01.07.2025 - Eliana Merle

Recent Filings

  • 01.22.2025 - 144 Report of proposed sale of securities
  • 01.21.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities

CARLSBAD, Calif.,Nov. 13, 2024/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:

Jefferies London Healthcare Conference, November 19-21st, 2024:

  • Todd Harris, CEO of TYRA, will participate in a fireside chat onTuesday, November 19th, at 2:00 pm GMT.
  • TYRA management will also participate in one-on-one investor meetings and B2B meetings.

36thAnnualPiper Healthcare Conference,December 3-5th, 2024,New York:

  • Mr. Harriswill participate in a fireside chat onWednesday, December 4th, at10:30 am ET.
  • TYRA management will also participate in one-on-one meetings with investors.

A live and archived webcast of the fireside chats will be available via theFor Investorspage on the TYRA website.

AboutTyra Biosciences

Tyra Biosciences, Inc.(Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is in development for the treatment of cancer in the SURF301 Phase 1/2 study and for achondroplasia in the BEACH301 Phase 2 study. TYRA is also developing TYRA-200, an investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based inCarlsbad, CA.

For more information about our science, pipeline and people, please visitwww.tyra.bioand engage with us onLinkedIn.

Contact:Amy Conradaconrad@tyra.bio

(PRNewsfoto/Tyra Biosciences, Inc.)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-upcoming-investor-conferences-302304521.html

SOURCETyra Biosciences

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com